Obesity Trial, Recruiting NCT07027033 Sponsor: Nantes University Hospital Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT07027033
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their informed consent to participate.
  • Women aged between 18 and 60 years old (inclusive).
  • People with obesity who meet the French health authority (HAS) criteria for bariatric (weight-loss) surgery — meaning a BMI of 35 or above with at least one related health condition, or a BMI above 40.
  • People of European descent, with both parents identified by the patient as being of European origin (this pilot study limits participation to reduce variability in results).
  • People who are using effective contraception, are abstinent, or have gone through menopause (as required for bariatric surgery eligibility).
  • People who have at least two of the following signs of insulin resistance at the time of joining: high fasting blood sugar or type 2 diabetes; high blood pressure (130/85 mmHg or above); low "good" (HDL) cholesterol (below 50 mg/dL); or high triglycerides (fats in the blood, at 150 mg/dL or above).
  • People covered by, or entitled to benefits under, a social security system.
  • People having their bariatric surgery performed at Nantes University Hospital (CHU de Nantes).

Who may not be able to join:

  • People whose diabetes medication has been changed in the past month.
  • People who are currently using insulin or are planning to start insulin before their bariatric surgery.
  • People whose cholesterol-lowering medication has been changed in the past three months.
  • People currently taking steroid medications (such as cortisone-type drugs) that affect the whole body.
  • People receiving antiviral treatment for HIV.
  • People taking dietary supplements that affect fat metabolism, such as certain functional margarines (e.g., Proactive, Danacol), omega-3 or other polyunsaturated fatty acid supplements, or similar products identified by the research team.
  • People with a condition where the pancreas does not produce enough digestive enzymes (exocrine pancreatic insufficiency).
  • People who are pregnant or breastfeeding.
  • People who have previously had an organ transplant.
  • People who are in legal custody or under a legal protection arrangement such as guardianship or trusteeship.
  • People with any other health condition that the research team considers could be harmed by participation or could affect the study.
  • People already participating in another clinical trial (except non-interventional studies or research into surgical or post-operative techniques).
  • People with Type 1 diabetes, a single-gene (monogenic) form of diabetes, or diabetes caused by another medical condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marie De Montrichard, PH, Nantes University Hospital

Phone: +332 40 08 30 22

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 July 2025
Est. completion
1 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Evaluate the effect of consuming oleic acid-rich sunflower oil versus conventional sunflower oil on cholesterol esterification within visceral white adipose tissue.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov